Xiaoxiang Zhou

1.1k total citations · 1 hit paper
20 papers, 766 citations indexed

About

Xiaoxiang Zhou is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Xiaoxiang Zhou has authored 20 papers receiving a total of 766 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Oncology. Recurrent topics in Xiaoxiang Zhou's work include Cancer Immunotherapy and Biomarkers (5 papers), Pancreatic and Hepatic Oncology Research (3 papers) and RNA modifications and cancer (3 papers). Xiaoxiang Zhou is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), Pancreatic and Hepatic Oncology Research (3 papers) and RNA modifications and cancer (3 papers). Xiaoxiang Zhou collaborates with scholars based in China and United States. Xiaoxiang Zhou's co-authors include Zhuoran Yao, Xuan Zhang, Huaxia Yang, Naixin Liang, Fengchun Zhang, Lejia Sun, Huayu Yang, Yilei Mao, Gang Xu and Meixi Liu and has published in prestigious journals such as Nucleic Acids Research, The Lancet Oncology and International Journal of Biological Macromolecules.

In The Last Decade

Xiaoxiang Zhou

18 papers receiving 761 citations

Hit Papers

Treatment-related adverse events of PD-1 and PD-L1 inhibi... 2021 2026 2022 2024 2021 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis
    2021 160 citations Xiaoxiang Zhou, Zhuoran Yao et al. The Lancet Oncology profile →

Peers

Xiaoxiang Zhou
Zhibo Zhang China
Nuttapong Ngamphaiboon Thailand
Maria Vadiaka Greece
May Cho United States
Salim Laghouati France
Susie Chin South Korea
Keishi Nakamura Japan
Krishna S. Gunturu United States
Anne‐Flore Plane France
Zhibo Zhang China
Xiaoxiang Zhou
Citations per year, relative to Xiaoxiang Zhou Xiaoxiang Zhou (= 1×) peers Zhibo Zhang

Countries citing papers authored by Xiaoxiang Zhou

Since Specialization
Citations

This map shows the geographic impact of Xiaoxiang Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoxiang Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoxiang Zhou more than expected).

Fields of papers citing papers by Xiaoxiang Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaoxiang Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoxiang Zhou. The network helps show where Xiaoxiang Zhou may publish in the future.

Co-authorship network of co-authors of Xiaoxiang Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaoxiang Zhou. A scholar is included among the top collaborators of Xiaoxiang Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaoxiang Zhou. Xiaoxiang Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Nuo, Xiaolan Liu, L. Wang, et al.. (2025). Prohibitins in infection: potential therapeutic targets. Future Microbiology. 20(4). 345–355. 1 indexed citations
2.
Gao, Yibo, Jiaming Xie, Yannan Yang, Xiaoxiang Zhou, & Jie He. (2025). Induction of cuproptosis enhances sensitivity and overcomes resistance to osimertinib in lung cancer. Signal Transduction and Targeted Therapy. 10(1). 390–390.
3.
Liu, Xiaolan, et al.. (2025). m6A-modified RIOK3 activated the NF-κB-signaling pathway by CDC42, promoting the replication and proliferation of enterovirus. International Journal of Biological Macromolecules. 305(Pt 2). 140988–140988. 1 indexed citations
4.
Wang, Lulu, Tao Sun, Xiaolan Liu, et al.. (2024). Myocarditis: A multi-omics approach. Clinica Chimica Acta. 554. 117752–117752. 2 indexed citations
5.
Li, Haochen, Tianxing Ma, Yixin Chen, et al.. (2024). scTML: a pan-cancer single-cell landscape of multiple mutation types. Nucleic Acids Research. 53(D1). D1547–D1556. 2 indexed citations
6.
Zhou, Xiaoxiang, Zhenjiang Li, Yangyan He, et al.. (2024). Acute Superior Mesenteric Artery Embolism With Infective Endocarditis: Is There a Role for Endovascular Treatment?. Journal of Endovascular Therapy.
7.
Liu, Xiaolan, et al.. (2023). Myocardial infarction complexity: A multi-omics approach. Clinica Chimica Acta. 552. 117680–117680. 8 indexed citations
8.
Zhou, Xiaoxiang, Zhengjiang Li, Yangyan He, et al.. (2023). Endovascular Treatment of Superior Mesenteric Artery Pseudoaneurysm Due to Infective Endocarditis With Stent-Graft. Journal of Endovascular Therapy. 30(5). 798–803. 2 indexed citations
9.
Zhou, Xiaoxiang, Zhuoran Yao, Hua Bai, et al.. (2021). Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. The Lancet Oncology. 22(9). 1265–1274. 160 indexed citations breakdown →
10.
Zhou, Xiaoxiang, Zhuoran Yao, Huaxia Yang, et al.. (2020). Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Medicine. 18(1). 87–87. 249 indexed citations
11.
Yang, Huaxia, Zhuoran Yao, Xiaoxiang Zhou, et al.. (2020). Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation. Clinical Immunology. 213. 108377–108377. 57 indexed citations
12.
Xu, Gang, Xiaoxiang Zhou, Yao Xiao, et al.. (2020). Identification of RASSF1A promoter hypermethylation as a biomarker for hepatocellular carcinoma. Cancer Cell International. 20(1). 547–547. 24 indexed citations
13.
Zhou, Xiaoxiang & Yu Liu. (2020). The Effect of Genetic Stability Molecules on the Movement of Human Embryonic Stem Cells. Nanoscience and Nanotechnology Letters. 12(2). 245–255. 1 indexed citations
14.
Yang, Huaxia, Zhuoran Yao, Xiaoxiang Zhou, et al.. (2020). Survival and prognostic factors of lung cancer patients with preexisting connective tissue disease: a retrospective cohort study. Annals of Translational Medicine. 8(21). 1415–1415. 3 indexed citations
15.
Yang, Huayu, Xiaoxiang Zhou, Lejia Sun, & Yilei Mao. (2019). Correlation Between PD-L2 Expression and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis. Frontiers in Oncology. 9. 47–47. 56 indexed citations
16.
Xu, Gang, Lejia Sun, Yunzhu Li, et al.. (2019). The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis. Frontiers in Oncology. 9. 897–897. 31 indexed citations
17.
Sun, Lejia, Huanhuan Yin, Meixi Liu, et al.. (2019). Impaired albumin function: a novel potential indicator for liver function damage?. Annals of Medicine. 51(7-8). 333–344. 98 indexed citations
18.
Zhou, Xiaoxiang, Lejia Sun, Dan Jing, et al.. (2018). Galectin-9 Expression Predicts Favorable Clinical Outcome in Solid Tumors: A Systematic Review and Meta-Analysis. Frontiers in Physiology. 9. 452–452. 58 indexed citations
19.
Yu, Hongliang, et al.. (2017). Identification of key genes and molecular mechanisms associated with dedifferentiated liposarcoma based on bioinformatic methods. OncoTargets and Therapy. Volume 10. 3017–3027. 10 indexed citations
20.
Shao, Hongxia, Xiaoxiang Zhou, Zhimin Wan, et al.. (2016). Impact of a potential glycosylation site at neuraminidase amino acid 264 of influenza A/H9N2 virus. Veterinary Microbiology. 196. 9–13. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhibo Zhang Breakdown of academic impact, for papers by Nuttapong Ngamphaiboon Breakdown of academic impact, for papers by Maria Vadiaka Breakdown of academic impact, for papers by May Cho Breakdown of academic impact, for papers by Salim Laghouati Breakdown of academic impact, for papers by Susie Chin Breakdown of academic impact, for papers by Keishi Nakamura Breakdown of academic impact, for papers by Krishna S. Gunturu Breakdown of academic impact, for papers by Anne‐Flore Plane
Rankless by CCL
2026